Orgenesis Inc. announced the appointment of Sav DiPasquale as President and Chief Executive Officer. Mr. DiPasquale succeeds Jacob BenArie, who has been appointed Chief Executive Officer of the company's private subsidiary, Orgenesis Ltd. Prior to joining Orgenesis, Mr. DiPasquale worked with GlaxoSmithKline Inc. There, DiPasquale served in various technology and marketing capacities including his most recent role as Vice President, Business Development and Corporate Planning.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7001 USD | +0.01% |
|
+9.91% | +39.82% |
12/07 | Orgenesis Inc. agreed to acquire remaining 50% stake in Theracell Laboratories SA. from Theracell Advanced Biotechnology Ltd for $13 million. | CI |
09/07 | Orgenesis Inc. Announces Board Changes | CI |
1st Jan change | Capi. | |
---|---|---|
+39.82% | 3.31Cr | |
-6.68% | 18TCr | |
-5.20% | 10TCr | |
-5.38% | 6.67TCr | |
+18.16% | 4.48TCr | |
-6.47% | 4.62TCr | |
+9.74% | 4.44TCr | |
+14.01% | 2.95TCr | |
+22.31% | 2.58TCr | |
-6.53% | 2.4TCr |
- Stock Market
- Equities
- ORGS Stock
- News Orgenesis Inc.
- Orgenesis Inc. Announces Executive Changes